Anti TNF medication (FOI)
Anti TNF medication (FOI)Produced by the Freedom of Information office
Authored by Government of Jersey and published on 20 August 2020.
Prepared internally, no external costs.
Please can you send me the information detailed below -
How many patients (in the Trust) were initiated on ANTI TNF (originator and biosimilar) over the last 12 months?
i) How many patients (in the Trust) have been initiated on biosimilar adalimumab?
ii) and what is the split by brand in the last 12 months for the following products?
How many patients have been initiated on these products?
• guselkumab (Tremfya)
• risankizumab (Skyrizi)
• brodalumab (Kyntheum)
• ixekizumab (Taltz)
In order to identify how many patients have been initiated within the last 12 months would require all the relevant patient names and then an interrogation of each patient’s medical record. It is estimated that to review the data held would take in excess of the time allowance applied under the Freedom of Information (Costs) (Jersey) Regulations 2014.
i) Please refer to Q1 above.
ii) The only biosimilar adalimumab product used is Imraldi.
Article 16 A scheduled public authority may refuse to supply information if cost excessive
(1) A scheduled public authority that has been requested to supply information may refuse to supply the information if it estimates that the cost of doing so would exceed an amount determined in the manner prescribed by Regulations.
Regulation 2 (1) of the Freedom of Information (Costs) (Jersey) Regulations 2014 allows an authority to refuse a request for information where the estimated cost of dealing with the request would exceed the specified amount of the cost limit of £500. This is the estimated cost of one person spending 12.5 working hours in determining whether the department holds the information, locating, retrieving and extracting the information.